Processa (NASDAQ: PCSA) CFO adds 1,984 shares in open-market buy

Rhea-AI Filing Summary

Processa Pharmaceuticals, Inc. Chief Financial Officer Russell Skibsted reported an open-market purchase of company shares. On April 15, 2026, he bought 1,984 shares of Common Stock at $2.97 per share in a direct ownership transaction, bringing his directly held stake to 4,308 shares.

Insider Trade Summary

Net Buyer: 1,984 shares ($5,892)

Net Buy 1 txn

Insider SKIBSTED RUSSELL

Role Chief Financial Officer

Bought 1,984 shs ($6K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,984	$2.97	$6K

Holdings After Transaction: Common Stock — 4,308 shares (Direct)

Footnotes (1)

Key Figures

Shares purchased: 1,984 shares Purchase price: $2.97 per share Direct holdings after transaction: 4,308 shares +1 more

4 metrics

Shares purchased 1,984 shares Open-market purchase of Common Stock on April 15, 2026

Purchase price $2.97 per share Price paid for each share in the transaction

Direct holdings after transaction 4,308 shares Total Common Stock directly owned following the purchase

Net buy shares 1,984 shares Net change in common shares from reported Form 4 activity

Key Terms

open-market purchase, non-derivative, transaction code "P", net-buy

4 terms

open-market purchase financial

"transaction_action": "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

non-derivative financial

""transaction_type": "non-derivative""

transaction code "P" financial

""transaction_code": "P""

net-buy financial

""netBuySellDirection": "net-buy""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SKIBSTED RUSSELL

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FLORIDA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/15/2026		P		1,984	A	$2.97	4,308	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Russell Skibsted by John J. Wolfel, as Attorney-in-Fact	04/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Processa Pharmaceuticals (PCSA) report?

Processa Pharmaceuticals reported that its CFO, Russell Skibsted, completed an open-market purchase of company shares. He acquired 1,984 shares of Common Stock at $2.97 per share, increasing his directly held position to a total of 4,308 shares after the transaction.

Who at Processa Pharmaceuticals (PCSA) bought shares and in what capacity?

Chief Financial Officer Russell Skibsted bought shares of Processa Pharmaceuticals. He filed as an officer of the company, and the Form 4 shows this was a direct ownership, open-market purchase of Common Stock rather than an indirect or entity-held position.

How many Processa Pharmaceuticals (PCSA) shares did the CFO buy and at what price?

The CFO bought 1,984 shares of Processa Pharmaceuticals Common Stock at a price of $2.97 per share. This open-market transaction is reported as a non-derivative purchase, meaning it involved common shares directly, not options or other derivatives.

What is the CFO’s Processa Pharmaceuticals (PCSA) shareholding after this Form 4?

Following the reported transaction, the CFO directly owns 4,308 shares of Processa Pharmaceuticals Common Stock. This figure reflects his total direct holdings after the 1,984-share open-market purchase disclosed, as stated in the Form 4’s post-transaction ownership field.

Was the Processa Pharmaceuticals (PCSA) insider trade a buy or a sell?

The insider trade was a buy. The Form 4 lists transaction code “P,” described as a purchase in an open-market or private transaction, and the normalized data classifies it as an open-market purchase with a net-buy direction of 1,984 shares.